The content on this site is intended for healthcare professionals only
The faculty answers to the questions of the audience.
Chairman conclusion with the take home messages.
Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
ASCO 2024: Lung cancer highlights
EAU 2024: Bladder cancer latest
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC
mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity
